Improvement of emodin on acute fatty liver in mice

WANG Shaojie; LI Xiaojie; XU Zhimeng; YAN Kang; CHEN Xi; JIANG Zhenzhou; ZHANG Luyong

doi:10.11665/j.issn.1000-5048.20170114

Journal of China Pharmaceutical University > 2017 > 48(1): 89-95. > DOI: 10.11665/j.issn.1000-5048.20170114

WANG Shaojie, LI Xiaojie, XU Zhimeng, YAN Kang, CHEN Xi, JIANG Zhenzhou, ZHANG Luyong. Improvement of emodin on acute fatty liver in mice[J]. Journal of China Pharmaceutical University, 2017, 48(1): 89-95. DOI: 10.11665/j.issn.1000-5048.20170114

Citation:

PDF (4315 KB)

Improvement of emodin on acute fatty liver in mice

More Information

Graphical Abstract

Abstract

Abstract

To observe the effects of emodin(Emo)on acute fatty liver in mice induced by DL-ethionine(DL-Eth)or tetracyclin(Tetra)and its potential mechanism, ICR mice of acute fatty liver model induced by DL-Eth were orally administered with Emo or positive control, ursodeoxycholic acid(UDCA)for 7 days. On day 7, except that the control and Emo groups were treated with vehicle control, animals were orally administered with DL-Eth to induce acute fatty liver model. ICR mice of acute fatty liver model induced by Tetra were orally administered with Emo or positive control, Dong Bao Gan Tai (DB)or total flavonoid C-glycosides from Abrus mollis extract(AME)for 7 days. From day 4, except that the control group was treated with vehicle control, animals were injected with Tetra intraperitoneally for 4 days to induce acute fatty liver model. Liver histopathological analyses were determined by HE staining. Serum aspartate transaminase(AST), alanine transaminase(ALT), serum triglyceride(TG), hepatic TG and hepatic total cholesteol(TC)were detected. The expression of phosphorylated AMP-activated kinase(p-AMPK), phosphorylated acetyl-CoA carboxylase(p-ACC), SREBP1 and fatty acid synthase(FAS)were determined by Western blot. The expression of fatty acid translocase(CD36), peroxisome proliferator activated receptor alpha(PPARα)and microsomal triglyceride transfer protein(MTTP)in liver were determined by RT-PCR. Compared with model groups, Emo could improve hepatocyte swelling and hepatic steatosis induced by DL-Eth or Tetra. Serum AST, ALT, serum TG, hepatic TG and hepatic TC were decreased by Emo significantly. DL-Eth-induced increase of fatty acid synthetase-associated protein was down-regulated by Emo. Fatty acid uptake was down-regulated by Emo; fatty acid oxidation and secretion were increased by Emo. Emo might be effective in preventing acute fatty liver in mice induced by DL-Eth or Tetra.
- emodin,
- DL-ethionine,
- tetracyclinacute,
- fatty liver,
- protection

FullText(HTML)

References (15)

References

[1]	Hardwick JP,Osei-Hyiaman D,Wiland H,et al.PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase(CYP4)isozymes:implications for prevention of lipotoxicity in fatty liver disease[J].PPAR Res,2009,2009:952734.
[2]	Portincasa P, Grattagliano I, Palmieri VO, et al. Nonalcoholic steatohepatitis:recent advances from experimental models to clinical management[J].Clin Biochem,2005,38(3):203-217.
[3]	Xue J,Ding W,Liu Y.Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice[J].Fitoterapia,2010,81(3):173-177.
[4]	Song P,Kim JH,Ghim J,et al.Emodin regulates glucose utilization by activating AMP-activated protein kinase[J].J Biol Chem,2013,288(8):5732-5742.
[5]	Heo SK, Yun HJ, Park WH, et al. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase-and mitochondrial-dependent apoptosis[J].J Cell Biochem,2008,105(1):70-80.
[6]	Wang CH, Gao ZQ, Ye B, et al. Effect of emodin on pancreatic fibrosis in rats[J].World J Gastroenterol,2007,13(3):378-382.
[7]	Liu WH,Qi Y,Jia D.Research progress on experimental models of non-alcoholic fatty liver disease[J].Shanghai J Tradit Chin Med(上海中医药杂志),2015,49(3):95-97.
[8]	Yoshizawa F,Mochizuki S,Doi M,et al.Ethionine-induced ATP depletion represses mTOR signaling in the absence of increases in AMP-activated protein kinase activity in the rat liver[J].Biosci Biotechnol Biochem,2009,73(9):1984-1988.
[9]	Yu HY,Wang BL,Zhao J,et al.Protective effect of bicyclol on tetracycline-induced fatty liver in mice[J].Toxicology,2009,261(3):112-118.
[10]	Choi YJ, Lee CH, Lee KY, et al. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice[J].Toxicol Sci,2015,145(2):273-282.
[11]	BénichouC.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276.
[12]	Kohjima M,Enjoji M,Higuchi N,et al.Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J].Int J Mol Med,2007,20(3):351-358.
[13]	Raghow R,Yellaturu C,Deng X,et al.SREBPs:the crossroads of physiological and pathological lipid homeostasis[J].Trends Endocrinol Metab,2008,19(2):65-73.
[14]	Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152.
[15]	Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice[J].Cell Metab,2011,13(4):376-388.

[1]	YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
[2]	YONG Qin, YUE Hanxun, SHI Min, HUANG Shiqin, ZHAO Xuan, YU Xian. Construction and in vitro evaluation of pH-responsive and tumor-targeted PTEN/PLGA-(HE)₁₀-MAP nanoparticles[J]. Journal of China Pharmaceutical University, 2021, 52(3): 301-310. DOI: 10.11665/j.issn.1000-5048.20210306
[3]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[4]	SONG Ke, PAN Hao, HAN Jiayi, CHEN Lijiang. Nano drug delivery system based strategies to target tumor microenvironment[J]. Journal of China Pharmaceutical University, 2018, 49(4): 392-400. DOI: 10.11665/j.issn.1000-5048.20180402
[5]	FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
[6]	SUN Jingfang, GUO Chunjing, ZHANG Yunduan, SONG Xiaoyan, LYU Jiantao, YIN Jungang, CHEN Daquan. Preparation and characterization of multi-functional targeting nano-carrier based on pH-redox tumor microenvironment[J]. Journal of China Pharmaceutical University, 2017, 48(3): 305-310. DOI: 10.11665/j.issn.1000-5048.20170309
[7]	HE Wei, QI Haixia, DONG Lei, ZHANG Junfeng. Research advances in drug delivery system targeting immune system[J]. Journal of China Pharmaceutical University, 2015, 46(5): 513-520. DOI: 10.11665/j.issn.1000-5048.20150501
[8]	ZHANG Zhiqing, WANG Fang, ZHOU Ting, ZHANG Guodong, WANG Xiufeng, LI Yunze. A DNA polyaptamer system as a targeted antitumor drug delivery[J]. Journal of China Pharmaceutical University, 2015, 46(4). DOI: 10.11665/j.issn.1000-5048.20150408
[9]	SU Zhigui, MO Ran, ZHANG Can. Advances of nano-drug delivery systems overcoming the physiological and pathological barriers of tumor[J]. Journal of China Pharmaceutical University, 2015, 46(1): 28-39. DOI: 10.11665/j.issn.1000-5048.20150103
[10]	KE Xue. Advances in targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(1): 9-15.

Cited By

Get Citation

PDF

XML

Article views (985) PDF downloads (1833)

Turn off MathJax

Article Contents

Abstract

References

Improvement of emodin on acute fatty liver in mice

Abstract

References

Related Articles

Catalog

Improvement of emodin on acute fatty liver in mice

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content